Fast track granted for Timber’s congenital ichthyosis candidate

The FDA has granted a fast track designation to Timber Pharmaceuticals’ topical isotretinoin for the treatment of the two most severe forms of congenital ichthyosis, the company announced in a press release.
The fast track designation for TMB-001, a topical formulation of isotretinoin that uses the Timber’s IPEG delivery system, will allow the company expedited reviews and FDA meetings to discuss the drug’s development in treating two types of congenital ichthyosis (CI) — X-linked recessive ichthyosis and autosomal recessive CI lamella ichthyosis.
“Based on the

The FDA has granted a fast track designation to Timber Pharmaceuticals’ topical isotretinoin for the treatment of the two most severe forms of congenital ichthyosis, the company announced in a press release.
The fast track designation for TMB-001, a topical formulation of isotretinoin that uses the Timber’s IPEG delivery system, will allow the company expedited reviews and FDA meetings to discuss the drug’s development in treating two types of congenital ichthyosis (CI) — X-linked recessive ichthyosis and autosomal recessive CI lamella ichthyosis.
“Based on the